Chronic Hepatitis B Pediatric Study

About Hepatitis B

Chronic hepatitis B (CHB) is a global public health issue. If left untreated, CHB can cause serious health problems, like scarring of the liver and liver damage. According to CDC (Centers for Disease Control and Prevention), an estimated 862,000 people in the U.S. are chronically infected with the hepatitis B virus. An infected mother can pass it to her baby at birth.

About Our Study

This study is evaluating the safety and efficacy of an investigational drug in children and adolescents (ages 2 to <18 years) with chronic hepatitis B virus infection.

If you think that your child or loved one would benefit from participating in this study, please email GS-US-320-1092@gilead.com.

Why Participate in This Study?

Eligible study participants may receive investigative study medication or placebo (an inactive substance)
Participants will receive medical care for their hepatitis B from a local study doctor at no cost and their health will be monitored closely at study visits
Participants may be eligible to participate in a long-term extension study
Participants may also receive reimbursement for study-related travel expenses

Eligibility

Note: This is not a complete list of eligibility criteria.

To participate, children must be:

Between ages 2 and 12
Diagnosed with chronic hepatitis B for more than six months
Has not been diagnosed with hepatitis C, hepatitis D or HIV
Is not currently receiving treatment for chronic hepatitis B
Has not been diagnosed with cancer in the last five years and is not currently being assessed for cancer

Locations

View Current Trial Locations